Nektar Therapeutics (NKTR) Cash from Financing Activities (2010 - 2026)

Nektar Therapeutics' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $529.5 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 7564885.71% year-over-year to $529.5 million; the TTM figure through Mar 2026 stood at $710.1 million (up 581955.74% YoY), while the FY2025 annual figure was $180.6 million, up 328.71% from the prior year.
• Cash from Financing Activities was $529.5 million for Q1 2026 at Nektar Therapeutics, up from $38.7 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $529.5 million in Q1 2026 to a low of $7000.0 in Q1 2025.
• Historically, Cash from Financing Activities has averaged $53.8 million across 5 years, with a median of $157000.0 in 2022.
• The sharpest annual moves came in 2025 and 2026: Cash from Financing Activities plunged 99.98% in 2025, then jumped 7564885.71% in 2026.
• A 5-year view of Cash from Financing Activities shows it stood at $103000.0 in 2022, then plunged by 88.35% to $12000.0 in 2023, then jumped by 591.67% to $83000.0 in 2024, then soared by 46491.57% to $38.7 million in 2025, then jumped by 1269.37% to $529.5 million in 2026.
• The last three Cash from Financing Activities figures came in at $529.5 million (Q1 2026), $38.7 million (Q4 2025), and $141.7 million (Q3 2025), per Business Quant data.